Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.49 |
| ▸ | PLK4 | O00444 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 5/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.39 |
| ▸ | PAK4 | O96013 | 2/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353182 | 1.00 | IGF1R (0.49) | IGF1RPLK4ADORA3ADORA2AMEN1 | |
| SCHEMBL30353133 | 0.99 | IGF1R (0.47) | IGF1RPLK4ADORA3ADORA2AMEN1 | |
| SCHEMBL30353153 | 0.90 | PLK4 (0.49) | IGF1RPLK4MEN1HTTKMT2A | |
| SCHEMBL30353145 | 0.89 | IGF1R (0.47) | IGF1RPLK4MEN1HTTKMT2A | |
| SCHEMBL29487416 | 0.89 | NTRK1 (0.47) | IGF1RPLK4AURKAAURKBPAK4 | |
| SCHEMBL30353173 | 0.85 | IGF1R (0.53) | IGF1RPLK4MEN1HTTKMT2A | |
| SCHEMBL30353131 | 0.85 | IGF1R (0.53) | IGF1RPLK4MEN1HTTKMT2A | |
| SCHEMBL30353161 | 0.84 | IGF1R (0.51) | IGF1RPLK4MEN1HTTKMT2A | |
| SCHEMBL30353180 | 0.83 | IGF1R (0.51) | IGF1RPLK4MEN1HTTKMT2A | |
| SCHEMBL30353160 | 0.79 | MEN1 (0.47) | IGF1RPLK4MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929854-B | Proliferation inhibitors | 千纸鹤治疗公司 | 2025-05-02 | — | — | CN | disclosed |
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | IGF1R 1819/4885PLK4 1/4885ADORA3 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.